The new patent entitled, ‘Neurotherapeutic treatment for sexual dysfunction,’ includes a method to treat erectile dysfunction and premature ejaculation in males, as well as enhancing libido in females.
Currently, the company has three drug candidates in Phase II clinical trials, Archexin, Serdaxin, and Zoraxel.
Rexahn president Rick Soni said the company is making progress in the development of Zoraxel, currently in Phase II trials for erectile dysfunction.